Bcp-All
Checking Date & Time
Reading File
BCP-ALL stands for B-cell precursor acute lymphoblastic leukemia. Let me search the textbooks comprehensively.
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Searching PubMed
"B-cell precursor ALL" OR "BCP-ALL" treatment
Reading File
Searching PubMed
"acute lymphoblastic leukemia"[MeSH Terms] AND "precursor B-Cell Lymphoblastic Leukemia-Lymphoma"[MeSH Terms]
I now have comprehensive information from multiple textbooks. Here is a complete overview of BCP-ALL (B-Cell Precursor Acute Lymphoblastic Leukemia):
BCP-ALL — B-Cell Precursor Acute Lymphoblastic Leukemia
Definition & Overview
BCP-ALL (also called B-ALL or pre-B ALL) is a neoplasm of immature B-cell precursors (lymphoblasts) arising primarily in the bone marrow. It constitutes ~85% of all ALL cases and is the most common cancer of children, with ~2,500 new cases/year in the US.
- Peak age: ~3 years (corresponding to peak normal bone marrow pre-B cell numbers)
- Sex: Slightly more frequent in boys
- Ethnicity: Highest incidence in Hispanic/Latino children
- Also occurs in adults, but with worse prognosis
— Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 556
Immunophenotype
Blasts express the following markers:
| Marker | BCP-ALL | Burkitt | Precursor T-ALL |
|---|---|---|---|
| TdT (nuclear) | + | − | + |
| HLA-DR | + | + | − |
| CD19 | + | + | − |
| CD10 (CALLA) | +/− | + | − |
| CD20 | −/+ | + | − |
| sIg | − | + | − |
| CD34 | + | − | variable |
| CD99 | + | + | |
| PAX5 | + | − |
Key subtypes by maturity:
- Pro-B ALL (~10%): CD19+/CD22+ only, CD10−
- Common ALL / CALLA+ ALL (~50–60%): CD19+/CD22+, CD10+ — best prognosis among B-ALL subtypes
- Pre-B ALL (~10%): above + intracytoplasmic immunoglobulin
- Mature B-ALL (<5%): surface immunoglobulin present
— Goldman-Cecil Medicine, p. 1921; Quick Compendium of Clinical Pathology, p. 256
Pathogenesis & Genetics
~90% of ALLs have chromosomal abnormalities. Key driver mutations disrupt transcription factors essential for early B-cell development:
| Gene/Abnormality | Translocation | Frequency | Prognosis |
|---|---|---|---|
| ETV6::RUNX1 (TEL::AML1) | t(12;21) | 25% of children | Good |
| Hyperdiploidy (>50 chr) | — | 25% of children | Good |
| BCR::ABL1 (Philadelphia+) | t(9;22) | 25% of adults, 3% of children | Poor |
| KMT2A (MLL) rearrangement | t(4;11), others | Infants | Poor |
| Hypodiploidy (<46 chr) | — | <5% | Poor |
| BCR-ABL1–like ALL | No t(9;22), similar expression | Variable | Poor |
| IGH::IL3 | t(5;14) | Rare | Background eosinophilia |
Other mutations include PAX5, TCF3, RUNX1, BCR::ABL1, KMT2A, PBX1. Complementary driver mutations affecting tyrosine kinase activity and RAS signaling are also common; deep sequencing suggests <10 total mutations produce full-blown ALL.
— Robbins, p. 557; Quick Compendium, p. 256
Clinical Presentation
Symptoms result from bone marrow replacement and pancytopenia:
- Fatigue, pallor (anemia)
- Fever, infections (neutropenia)
- Bleeding/petechiae (thrombocytopenia)
- Bone pain, lymphadenopathy, hepatosplenomegaly
- CNS involvement (headache, cranial nerve palsies)
Treatment
Treatment is divided into three phases:
1. Induction (3–4 weeks)
- Vincristine + prednisone + L-asparaginase ± daunorubicin
- CR achieved in >95% of children, ~80–90% of adults
- For CD20+ Ph− ALL: add rituximab (improves outcomes)
2. Post-Remission (Consolidation + Maintenance)
- Consolidation: high-dose methotrexate, cyclophosphamide, cytarabine (6–8 intensive courses)
- Maintenance: daily 6-mercaptopurine + weekly methotrexate for 2–3 years
- Addition of blinatumomab (anti-CD19 × anti-CD3 bispecific antibody) during consolidation → molecular remission rates ↑, >90% survival at 18 months
3. CNS Prophylaxis
- Intrathecal methotrexate ± cytarabine (4 cycles, alternating)
Relapsed/Refractory BCP-ALL
- Blinatumomab (BiTE): improves DFS and OS in relapsed B-ALL and measurable residual disease (MRD+)
- Inotuzumab ozogamicin (anti-CD22 antibody-drug conjugate): ↑ CR rate and PFS vs chemo (risk: sinusoidal obstruction syndrome)
- CAR-T cells (anti-CD19 or anti-CD22): very high CR rates in refractory/2nd+ relapse; toxicities include cytokine release syndrome and neurotoxicity
- Hematopoietic stem cell transplant (HSCT): curative in 50–60% when done in first remission; 20–40% in relapse
— Goldman-Cecil Medicine, pp. 1924–1925
Prognosis
| Population | 5-Year Survival |
|---|---|
| Children | ~90% |
| Adolescents/young adults (≤40 yr) | 65–75% |
| Adults >60 years | <20% |
Favorable prognostic factors: younger age, low WBC at diagnosis, favorable cytogenetics (ETV6::RUNX1, hyperdiploidy), achievement of MRD-negative remission.
Poor prognostic factors: Ph+ (BCR::ABL1), KMT2A rearrangement (infants), hypodiploidy, BCR-ABL1–like ALL, older age.
— Goldman-Cecil Medicine, p. 1925; Quick Compendium, p. 256
This is a shared conversation. Sign in to Orris to start your own chat.